News & Updates

Treatment with tirzepatide, compared with lifestyle intervention alone, helps prevent the incidence of new or progressive diabetic retinopathy (DR) and its complications among patients with diabetes and overweight or obesity, suggests a study.

Updated results from the phase III PULSAR trial show that intravitreal (IVT) aflibercept 8 mg, when administered at extended dosing intervals of up to 20 weeks, led to visual gains and anatomic improvements comparable to the 2-mg dose, with no new safety concerns over 96 weeks, in treatment-naïve individuals with neovascular age-related macular degeneration (nAMD).

In the treatment of patients with proliferative diabetic retinopathy, brolucizumab outperforms panretinal laser photocoagulation in terms of preserving visual acuity, according to the international phase III CONDOR trial.